{"title":"Interpretation of Thyroid Autoantibodies in Hyperthyroidism","authors":"Han-sang Baek, D. Lim","doi":"10.3904/kjm.2023.98.3.132","DOIUrl":null,"url":null,"abstract":"Thyrotoxicosis is a clinical state with a variety of various etiologies that results from excess thyroid hormones, including hyperthyroidism and thyroiditis. Graves' disease (GD) is a well-known autoimmune thyroid disease that causes hyperthyroidism, and its pathogenesis is mainly driven by the thyroid-stimulating hormone receptor antibody (TSHRAb), which is highly specific for GD. Measuring the TSHRAb is a fast and accurate diagnostic tool for GD and has been used to monitor disease activity and the treatment response. However, conventional TSH-binding inhibitory immunoglobulin (TBII) does not differentiate between stimulating, blocking, or neutral antibodies. In contrast, thyroid stimulatory immunoglobulin bioassays differentiate between stimulating and blocking antibodies and have comparably high sensitivity and specificity to TBII for GD. We also discuss the role of thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) in thyrotoxicosis, although they are less specific than TSHRAb for GD. TPOAb is associated with autoimmune thyroiditis, while TgAb appears with TPOAb in patients with autoimmune thyroid disease. In addition, TPOAb or TgAb may be associated with a low recurrence of GD after discontinuing anti-thyroid drugs. Clinicians should interpret thyroid autoantibodies in the context of the patient's clinical presentation and consider their implications to manage and monitor thyrotoxicosis.","PeriodicalId":84452,"journal":{"name":"Chungang uihak = The Korean central journal of medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chungang uihak = The Korean central journal of medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3904/kjm.2023.98.3.132","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Thyrotoxicosis is a clinical state with a variety of various etiologies that results from excess thyroid hormones, including hyperthyroidism and thyroiditis. Graves' disease (GD) is a well-known autoimmune thyroid disease that causes hyperthyroidism, and its pathogenesis is mainly driven by the thyroid-stimulating hormone receptor antibody (TSHRAb), which is highly specific for GD. Measuring the TSHRAb is a fast and accurate diagnostic tool for GD and has been used to monitor disease activity and the treatment response. However, conventional TSH-binding inhibitory immunoglobulin (TBII) does not differentiate between stimulating, blocking, or neutral antibodies. In contrast, thyroid stimulatory immunoglobulin bioassays differentiate between stimulating and blocking antibodies and have comparably high sensitivity and specificity to TBII for GD. We also discuss the role of thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) in thyrotoxicosis, although they are less specific than TSHRAb for GD. TPOAb is associated with autoimmune thyroiditis, while TgAb appears with TPOAb in patients with autoimmune thyroid disease. In addition, TPOAb or TgAb may be associated with a low recurrence of GD after discontinuing anti-thyroid drugs. Clinicians should interpret thyroid autoantibodies in the context of the patient's clinical presentation and consider their implications to manage and monitor thyrotoxicosis.
甲状腺毒症是一种由甲状腺激素过多引起的多种病因的临床状态,包括甲状腺功能亢进和甲状腺炎。Graves' s disease (GD)是一种众所周知的甲状腺功能亢进的自身免疫性疾病,其发病机制主要由促甲状腺激素受体抗体(TSHRAb)驱动,该抗体对GD具有高度特异性。测量TSHRAb是一种快速准确的GD诊断工具,已被用于监测疾病活动性和治疗反应。然而,传统的tsh结合抑制性免疫球蛋白(TBII)不能区分刺激、阻断或中性抗体。相比之下,甲状腺刺激免疫球蛋白生物测定法区分刺激抗体和阻断抗体,对GD的TBII具有相当高的敏感性和特异性。我们还讨论了甲状腺过氧化物酶抗体(TPOAb)和甲状腺球蛋白抗体(TgAb)在甲状腺毒症中的作用,尽管它们对GD的特异性不如TSHRAb。TPOAb与自身免疫性甲状腺炎相关,而TgAb在自身免疫性甲状腺疾病患者中与TPOAb一起出现。此外,TPOAb或TgAb可能与停用抗甲状腺药物后GD复发率低有关。临床医生应该在患者临床表现的背景下解释甲状腺自身抗体,并考虑其对管理和监测甲状腺毒症的影响。